Cognition Therapeutics Seeks FDA Alignment on DLB Trial Endpoints
Event summary
- Cognition Therapeutics scheduled a Type C meeting with the FDA for October 20, 2026, to align on endpoints for its Phase 3 trial of zervimesine (CT1812) in DLB.
- The trial will focus on psychosis symptoms, including hallucinations and delusions, as a primary outcome.
- The Phase 3 study will enroll DLB patients with psychosis symptoms, randomized to receive either 100 mg of zervimesine or placebo for nine months.
- Zervimesine previously showed an 89% reduction in psychosis progression compared to placebo in a Phase 2 trial.
The big picture
Cognition Therapeutics is positioning zervimesine as a potential disease-modifying treatment for DLB, a neurodegenerative disorder with no approved therapies. The strategic focus on psychosis symptoms aligns with FDA guidance and addresses a significant unmet need, potentially expanding the market for neurodegenerative treatments. The outcome of the upcoming FDA meeting will be critical in shaping the regulatory path forward for zervimesine.
What we're watching
- Regulatory Alignment
- Whether the FDA will approve psychosis as a primary endpoint for DLB trials, which could set a precedent for future neurodegenerative disease treatments.
- Trial Execution
- The pace at which Cognition can enroll and complete the Phase 3 trial, given the challenges of recruiting DLB patients with psychosis symptoms.
- Market Potential
- How successful zervimesine could be in addressing the critical unmet need for DLB treatments, particularly in managing psychosis symptoms.
Related topics
